Dario and GreenKey Health Announce Strategic Commercial Agreement to Transform Chronic Condition Management and Sleep Health for Payers Nationwide

Rhea-AI Summary

DarioHealth (NASDAQ: DRIO) has announced a strategic commercial agreement with GreenKey Health to address the $150 billion sleep apnea market. The collaboration combines Dario's AI-powered cardiometabolic and behavioral health solutions with GreenKey's sleep-first approach to obstructive sleep apnea (OSA) management.

The partnership targets 29 million Americans affected by sleep apnea, with up to 80% of moderate to severe cases currently undiagnosed. The joint solution aims to improve member outcomes, reduce healthcare costs, and increase productivity through integrated behavioral health, sleep, and cardiometabolic care. The initiative will focus on engaging Commercial, ASO, Medicaid, Medicare Advantage plans, self-funded employers, and other healthcare stakeholders.

Positive

• Targets massive $150 billion sleep apnea market opportunity
• Addresses large untapped market with 80% of moderate to severe cases undiagnosed
• Creates new revenue stream through integrated solution for payers
• Expands market reach across multiple healthcare segments including Commercial, Medicaid, and Medicare Advantage plans

Negative

• Success depends on securing payer contracts in competitive market
• Implementation and integration challenges may affect rollout
• ROI and cost savings yet to be proven in real-world application

Insights

Healthcare Business Analyst

Dario's strategic partnership with GreenKey targets untapped $150B sleep apnea market, creating potential new revenue streams and competitive advantage.

This strategic commercial agreement between DarioHealth and GreenKey Health represents a significant market expansion for Dario into the $150 billion sleep apnea space affecting 29 million Americans. The collaboration strategically integrates Dario's AI-powered cardiometabolic and behavioral health solutions with GreenKey's sleep-first approach, creating a comprehensive chronic care management system.

The partnership's business model targets multiple revenue channels, including Commercial, ASO, Medicaid, Medicare Advantage plans, self-funded employers, and value-based care providers. This diversified approach mitigates market penetration risks while maximizing distribution potential.

What makes this particularly noteworthy is the clinical integration strategy. The press release highlights that 80% of moderate to severe sleep apnea cases remain undiagnosed, revealing a substantial detection gap. The integrated solution aims to create a comprehensive patient identification funnel that connects sleep issues with Dario's existing expertise in managing diabetes, obesity, hypertension, and depression.

From a competitive positioning standpoint, this collaboration creates a differentiated offering in the fragmented chronic care management space by addressing interconnected conditions through a unified platform. The emphasis on data-driven insights suggests the partnership will focus on demonstrating measurable ROI to payers – critical for adoption in value-based care environments.

While the partnership shows strategic promise by connecting complementary capabilities and targeting a significant unmet need, the press release lacks specific implementation timelines or financial projections, making immediate revenue impact difficult to quantify. Success will ultimately depend on execution, payer adoption rates, and the partners' ability to demonstrate measurable improvements in both clinical outcomes and cost reduction.

Dario and GreenKey Join Forces to Target $150 Billion Sleep Apnea Market, Addressing 29 Million Americans with Unmet Needs Through Integrated Chronic Care Solution

NEW YORK and SAN FRANCISCO, June 26, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ('Dario' or the 'Company'), a leader in the global digital health market, today announced a strategic commercial agreement with GreenKey Health ('GreenKey'), an innovator in value-based sleep health solutions, to bring the comprehensive care program to payers nationwide. The collaboration leverages the strengths of both companies to deliver a tiered, data-driven solution for improving member health outcomes, reducing healthcare costs, and enhancing productivity through the integration of behavioral health, sleep, and cardiometabolic care. The collaboration targets the $150 billion sleep apnea market affecting over 29 million Americans, with up to 80% of moderate to severe cases currently undiagnosed¹.

This collaboration unites Dario's clinically validated cardiometabolic and behavioral artificial intelligence ('AI')-powered health solutions with GreenKey's 'sleep-first' approach to obstructive sleep apnea ('OSA') management. Together, the organizations aim to drive awareness, and secure payer contracts, through a robust multi-channel marketing plan designed to engage Commercial, ASO ('Administrative Services Only'), Medicaid, and Medicare Advantage plans, as well as self-funded employers, consultants, brokers, and value-based care providers.

The immediate joint launch of the collaboration will focus on engaging large payers as strategic channel collaborators while building a national network of aligned service providers. The strategic initiatives will utilize a mix of targeted outreach, thought leadership, and high-impact content to connect with decision-makers and advance adoption of this innovative, value-based care model.

OSA affects over 29 million Americans, with up to 80% of moderate to severe cases undiagnosed, driving more than $150 billion in annual U.S. costs due to associated cardiometabolic and behavioral comorbidities like diabetes, obesity, hypertension, and depression². As payers increasingly shift toward value-based care, there is a growing need for integrated solutions that address these interconnected conditions. Combining GreenKey's sleep-first approach with Dario's proven cardiometabolic and behavioral health programs delivers a holistic, data-driven solution that improves clinical outcomes, reduces healthcare costs, and meets the market demand for comprehensive, high-return on investment ('ROI') chronic condition management.

"We believe that this agreement marks a pivotal step forward in reshaping how chronic conditions like sleep apnea and cardiometabolic disorders are addressed in tandem," said Steven Nelson, Chief Commercial Officer at Dario. "By combining our real-time engagement and data-driven platform with GreenKey's powerful OSA cost-saving engine, we are offering payers a differentiated, value-based care solution that not only improves health outcomes but significantly reduces the total cost of care. This collaboration opens access to a multi-billion-dollar market and aligns perfectly with our mission to provide integrated, data-driven solutions for the most prevalent and costly chronic conditions facing healthcare today."

This joint solution is a comprehensive, tiered program that delivers:

• Improved Member Outcomes through enhanced sleep health, optimized GLP-1 utilization, and effective comorbidity management
• Reduced Healthcare Costs with decreased Emergency Department and inpatient utilization
• Increased Productivity from better sleep and overall health
• Actionable Data Insights to continuously optimize program performance

Studies have shown that even weight loss of 10% can lead to a substantial reduction in apnea–hypopnea index ('AHI'), indicating a decrease in the severity of sleep apnea. AHI is a simple measure of how often during sleep someone either completely stops breathing or breathes much more shallowly. "We are excited to collaborate with Dario, a proven leader in digital health engagement and outcomes," said Michael Markus, Chief Executive Officer of GreenKey Health. "Our collaboration offers payers a unique opportunity to activate a clinically integrated funnel that identifies the right patients for the right programs—starting with sleep and extending through behavior and cardiometabolic health. This is how we redefine chronic care for the modern healthcare system."

By aligning behavioral health and sleep-first strategies with precision cardiometabolic interventions, the Dario-GreenKey collaboration provides a superior offering that meets the growing demand for integrated, measurable chronic care solutions.

^1,2 https://aasm.org/economic-burden-of-undiagnosed-sleep-apnea-in-u-s-is-nearly-150b-per-year/?utm_source=chatgpt.com  

About DarioHealth Corp.

DarioHealth Corp. (NASDAQ: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Our platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.

Our user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.

Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.

About GreenKey Health

GreenKey Health is a pioneering healthcare company focused on addressing obstructive sleep apnea through value-based care. Its GreenKey4Life platform empowers payers to improve outcomes, reduce costs, and unlock productivity gains through an integrated, sleep-first approach to chronic condition management.

For more information, visit www.greenkey.health. 

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the benefits of the collaboration between the Company and GreenKey; that the collaboration intends to engage large payers and build a national service provider network; that the collaboration will improve outcomes, reduce costs, and meet market demand; that the collaboration opens access to a multi-billion-dollar market; and that the collaboration will provide a solution to meet growing demand for measurable, integrated care. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contact:
Mary Mooney
VP Marketing
+1-312-593-4280

DarioHealth Investor Relations Contact
Kat Parrella
Investor Relations Manager
kat@dariohealth.com
+315-378-6922
GreenKey Health Communications
media@greenkeyhealth.com

Logo: https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/dario-and-greenkey-health-announce-strategic-commercial-agreement-to-transform-chronic-condition-management-and-sleep-health-for-payers-nationwide-302492166.html

SOURCE DarioHealth Corp.

FAQ

What is the strategic agreement between DarioHealth and GreenKey Health?

DarioHealth and GreenKey Health have partnered to deliver an integrated chronic care solution combining Dario's AI-powered cardiometabolic and behavioral health solutions with GreenKey's sleep-first approach to OSA management, targeting the $150 billion sleep apnea market.

How many Americans are affected by sleep apnea according to DRIO's announcement?

According to the announcement, over 29 million Americans are affected by sleep apnea, with up to 80% of moderate to severe cases remaining undiagnosed.

What are the main benefits of the Dario-GreenKey collaboration?

The collaboration offers improved member outcomes through enhanced sleep health and comorbidity management, reduced healthcare costs through decreased emergency department visits, increased productivity, and actionable data insights for program optimization.

Which market segments will DarioHealth and GreenKey target?

The partnership will target Commercial, ASO (Administrative Services Only), Medicaid, and Medicare Advantage plans, as well as self-funded employers, consultants, brokers, and value-based care providers.

How does sleep apnea treatment relate to weight management in DRIO's program?

Studies cited in the announcement show that a 10% weight loss can significantly reduce the apnea-hypopnea index (AHI), indicating a decrease in sleep apnea severity, which is addressed through the integrated care approach.